Bazedoxifene-induced vasodilation and inhibition of vasoconstriction is significantly greater than estradiol.

ABSTRACT:

Objective

A new strategy for menopausal hormone therapy replaces medroxyprogesterone with the selective estrogen receptor modulator bazedoxifene. While the agonist or antagonist activity of bazedoxifene has been examined in other tissues, the current study explored the impact of bazedoxifene on resistance artery reactivity. We hypothesized that bazedoxifene may induce greater vasoprotective effects than estradiol due to enhanced activation of the G-protein-coupled estrogen receptor.

Methods

We measured the vasodilation of mesenteric resistance arteries from adult male and female wild-type and G-protein-coupled estrogen receptor knockout mice (n = 58) in response to increasing concentrations of bazedoxifene, medroxyprogesterone, and estradiol, and also the impact of these com

SUBMITTER: Zimmerman MA 

PROVIDER: S-EPMC6344253 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature